You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
High Power, Mid-Infrared Fiber Supercontinuum Light Source
SBC: MESA PHOTONICS LLC Topic: N/AModern supercontinuum (SC) light sources are generated by non-linear interactions between ultrashort pulse lasers and optical fibers. Output in near-ultraviolet to near-infrared wavelength ranges has been demonstrated. These light sources have high brightness and are spatially coherent. Recently, output to 4.5 µm was achieved using fluoride glass fibers; optical absorption by the fiber prevents l ...
SBIR Phase I 2008 Department of CommerceNational Institute of Standards and Technology -
STTR Phase I: The Development of Quantum Dot Materials for Ultrafast Laser Applications
SBC: MESA PHOTONICS LLC Topic: MMThis award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5). This Small Business Technology Transfer Phase I project is to develop quantum dot-based materials to enable the development of low cost, ultrafast lasers. By utilizing new quantum dot semiconductor materials, ultrafast lasers that are monolithic, robust, and inexpensive are planned. Successful comp ...
STTR Phase I 2009 National Science Foundation -
High Power, Mid-Infrared Fiber Supercontinuum Light Source
SBC: MESA PHOTONICS LLC Topic: N/AModern supercontinuum (SC) light sources are generated by non-linear interactions between ultrashort laser pulses and optical fibers. These light sources have high brightness and are spatially coherent. Output in near-ultraviolet to near-infrared wavelength ranges has been demonstrated. SC wavelength ranges are constrained by the transmission and dispersion properties of the fibers. Previously, ou ...
SBIR Phase II 2009 Department of CommerceNational Institute of Standards and Technology -
Low cost ammonia sensor for agricultural emissions
SBC: MESA PHOTONICS LLC Topic: 84Ammonia gas that is emitted from agriculture can create health problems for workers and, surprisingly, for people far from the agricultural operation. Once released into the air, the ammonia undergoes a series of chemical reactions that lead to small particles (known as PM2.5) that are inhaled deep into people's lungs. Those particles can trigger asthma and are linked to increased risk of hea ...
SBIR Phase I 2012 Department of Agriculture -
GALECTIN 1 FOR MULTIPLE SCLEROSIS
SBC: MANDALMED INC Topic: N/AN/A
SBIR Phase I 1999 Department of Health and Human Services -
N/A
SBC: MANDALMED INC Topic: N/AN/A
SBIR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health -
THERAPY OF SPINAL CORD INJURY WITH NEUROTROPHIC FACTORS
SBC: MANDALMED INC Topic: N/AN/A
STTR Phase I 1999 Department of Health and Human Services -
Novel Treatment for Breast Cancer: Truncated Galectin-3
SBC: MANDALMED INC Topic: N/ADESCRIPTION (provided by applicant): Despite the available treatments breast cancer ranks second as the cause of death from cancer in women primarily due to metastases of the primary tumor to other sites in the body. We will extend our preliminary study of the anticancer activity of recombinant human galectin-3 N-termin ...
SBIR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
Novel Ex Vivo Gene Therapy for Spinal Cord Injury
SBC: MANDALMED INC Topic: N/ADESCRIPTION (provided by applicant): There are approximately 10,000 traumatic spinal cord injuries in the United States each year. The average age of injury is 31 years. The majority (90%) of individuals survive and live near-normal life spans. Cost of treating these injuries is very high and does not lead to complete recovery. Spinal cord injury can result in progressive axonal degeneration, vari ...
SBIR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health -
NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY
SBC: MANDALMED INC Topic: N/ADESCRIPTION (provided by applicant): The goal of the Phase I research is to develop ex vivo gene therapy that will achieve long-term, localized delivery of human neurotrophin-3 (hNT-3) in the rat contusion model of spinal cord injury. Our overall goal is to develop cell-based delivery of neurotrophins and other proteins as therapy for acute spinal cord injury. The follow ...
SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health